Form 4: Armata CEO Birx Sells Shares for Tax Obligations

Armata Pharmaceuticals CEO Deborah Birx reported the sale of 4,919 common shares to cover tax obligations related to restricted stock unit settlement.

Summary

• Deborah Birx, Chief Executive Officer and Director of Armata Pharmaceuticals, Inc. (ARMP), reported a transaction on March 14, 2026.
• The transaction involved the disposition of 4,919 shares of Armata Pharmaceuticals common stock.
• The shares were disposed of at a price of $10.54 per share.
• This disposition was categorized as an 'F' transaction code, indicating shares withheld by the company to satisfy income tax and withholding remittance obligations.
• The withholding was in connection with the net settlement of restricted stock units.
• Following this transaction, Deborah Birx beneficially owns 212,458 shares of Armata Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting a standard tax-related disposition of shares following the vesting of restricted stock units, rather than a discretionary sale indicating a change in sentiment.

Positives

• The underlying event of restricted stock unit (RSU) vesting represents earned compensation for the executive, indicating potential achievement of performance milestones or completion of service periods.

Negatives

• No direct negatives related to company performance or outlook are indicated by this routine tax-related transaction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. This specific filing details a tax-related sale, which is a common occurrence when restricted stock units vest, and does not typically reflect a change in management's confidence in the company's future.

Comparison to Industry Standards

• This transaction is a standard practice for executives in publicly traded companies across various industries, including biotechnology, when restricted stock units vest. It is a common mechanism for covering tax liabilities associated with equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale, not a discretionary sale indicating a change in confidence.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically signal a change in management's outlook or the company's fundamentals, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Armata Pharmaceuticals, ARMP, Deborah Birx, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, CEO, Director